MM

Martin Münchbach

Pureos Bioventures

Zurich

Invests in

Stages:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Skills

Pharmaceutical Industry
Biotechnology
Venture Capital
Medical Devices
Lifesciences
Technology Transfer
Commercialization
Clinical Development
R&D
Strategy
Mergers & Acquisitions
Biopharmaceuticals
Start-ups
Licensing
Corporate Development
Venture Financing
Angel Investing
Oncology
Patents
Due Diligence

Education

Work Experience

  • Managing Partner

    2017

    Pureos is a venture capital fund located in Zurich to exclusively invest in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats.

  • Board Member

    2019

    The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years’ experience.

  • Board Member

    2021

River Renal Inc

2021

  • Board Member

    2021

  • Board Member

    2019

    Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC). The company has in-licensed platform technologies and a monoclonal antibody drug candidate which are the result of more than a decade of research from the University of Strasbourg and Inserm, the French National Institutes of Health and the Mount Sinai Hospital, New York

2011 - 2022

  • Board Member

    2011 - 2022

    binx health has the world’s fastest FDA-cleared molecular platform for CT/NG testing. The technology brings rapid, accurate and convenient infectious disease testing to people where they live, work and shop.

Tioga Pharmaceuticals, Inc.

2005 - 2022

  • Board Member

    2005 - 2022

  • Board Observer

    2020 - 2021

    Lava Therapeutics B.V. is a biotechnology company, founded in 2016, that creates and develops next generation γδ T cell engaging bispecific antibodies for the treatment of cancer. Our first-in-class immuno-oncology approach activates γδ T cells in a tumor target dependent manner. The objective of Lava Therapeutics B.V is to develop potent, safe and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells.

  • Senior Investment Manager Private Equity

    2004 - 2021

  • Board Member

    2013 - 2019